Department of Biomedical Sciences, City University of Hong Kong, Hong Kong, China.
Biotechnology and Health Centre, City University of Hong Kong Shenzhen Research Institute, Shenzhen, China.
Proc Natl Acad Sci U S A. 2019 Oct 15;116(42):20969-20976. doi: 10.1073/pnas.1906843116. Epub 2019 Sep 30.
RNA-guided CRISPR-Cas9 proteins have been widely used for genome editing, but their off-target activities limit broad application. The minimal Cas9 ortholog from (SaCas9) is commonly used for in vivo genome editing; however, no variant conferring high genome-wide specificity is available. Here, we report rationally engineered SaCas9 variants with highly specific genome-wide activity in human cells without compromising on-target efficiency. One engineered variant, referred to as SaCas9-HF, dramatically improved genome-wide targeting accuracy based on the genome-wide unbiased identification of double-stranded breaks enabled by sequencing (GUIDE-seq) method and targeted deep sequencing analyses. Among 15 tested human endogenous sites with the canonical NNGRRT protospacer adjacent motif (PAM), SaCas9-HF rendered no detectable off-target activities at 9 sites, minimal off-target activities at 6 sites, and comparable on-target efficiencies to those of wild-type SaCas9. Furthermore, among 4 known promiscuous targeting sites, SaCas9-HF profoundly reduced off-target activities compared with wild type. When delivered by an adeno-associated virus vector, SaCas9-HF also showed reduced off-target effects when targeting in a human retinal pigmented epithelium cell line compared with wild type. Then, we further altered a previously described variant named KKH-SaCas9 that has a wider PAM recognition range. Similarly, the resulting KKH-HF remarkably reduced off-target activities and increased on- to off-target editing ratios. Our finding provides an alternative to wild-type SaCas9 for genome editing applications requiring exceptional genome-wide precision.
RNA 引导的 CRISPR-Cas9 蛋白已被广泛用于基因组编辑,但它们的脱靶活性限制了其广泛应用。来自 Staphylococcus aureus 的最小 Cas9 直系同源物(SaCas9)通常用于体内基因组编辑;然而,没有可提供高基因组特异性的变体。在这里,我们报告了经过合理设计的 SaCas9 变体,它们在不影响靶标效率的情况下,在人类细胞中具有高度特异性的全基因组活性。一种工程化变体,称为 SaCas9-HF,基于测序(GUIDE-seq)方法和靶向深度测序分析对双链断裂的全基因组无偏识别,极大地提高了全基因组靶向准确性。在测试的 15 个具有典型 NNGRRT 原间隔基序(PAM)的人类内源性靶标中,SaCas9-HF 在 9 个靶标上没有检测到脱靶活性,在 6 个靶标上仅有最小的脱靶活性,并且与野生型 SaCas9 的靶标效率相当。此外,在 4 个已知的混杂靶向位点中,SaCas9-HF 与野生型相比显著降低了脱靶活性。当通过腺相关病毒载体递送时,与野生型相比,SaCas9-HF 靶向人视网膜色素上皮细胞系中的 时,脱靶效应也降低。然后,我们进一步改变了先前描述的具有更宽 PAM 识别范围的变体,名为 KKH-SaCas9。同样,所得的 KKH-HF 显著降低了脱靶活性并提高了靶标到脱靶编辑的比值。我们的发现为需要极高基因组精度的基因组编辑应用提供了替代野生型 SaCas9 的选择。